ITGAX and neoplasm: To analyze DC cross‐priming, we sorted out DCs (CD11c+CD103+MHCIIhigh) from draining lymph nodes of MC38‐OVA tumor‐bearing mice subjected to Mn‐N/C or vehicle treatment and co‐cultured them with OT‐1 CD8+T cells, known to react with the OVA peptide 257–264, for 3 days (Figure 3I).